17th Congress of ECCO: European Crohn’s and Colitis Organisation*

Download All
February 16-19, 2022; Virtual
Review expert commentary on key studies of new and emerging therapies from ECCO 2022.*
Uma Mahadevan, MD
Bruce E. Sands, MD, MS

Clinical Impact of New Data on Crohn’s Disease and Ulcerative Colitis

Download these slides for expert insights on key trials presented at ECCO 2022 and the impact the data will have in the management of patients with Crohn disease and ulcerative colitis.

Uma Mahadevan, MD Bruce E. Sands, MD, MS Released: May 6, 2022

Recent acceleration in the development of biologics and small-molecule inhibitors for patients with inflammatory bowel disease has led to an expanded and increasingly complex treatment landscape. Here’s my take.

Bruce E. Sands, MD, MS Released: May 13, 2022

In this webcast, expert faculty translate and discuss the most clinically significant data from ECCO 2022 into evidence-based management strategies for patients with Crohn disease and ulcerative colitis.

Uma Mahadevan, MD Bruce E. Sands, MD, MS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: May 19, 2022 Expired: May 18, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings